Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN) announced the grant of non-qualified stock option awards to seven new employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OptiNose, Inc. (NASDAQ:OPTN) announced the grant of non-qualified stock option awards to seven new employees. A total of 60,000 shares were awarded to incentivize employment acceptance. The options were granted outside the company’s 2010 Stock Incentive Plan, adhering to Nasdaq Rule 5635(c)(4). Exercise prices were set at $2.51 and $2.57, corresponding to closing prices on grant dates of August 16 and 23, 2021. These options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining in monthly installments.
Positive
- Granting of stock options to seven new employees may enhance talent acquisition and retention.
- The exercise prices of the options are set at competitive levels, reflecting recent market valuations.
Negative
- None.
Details
News Market Reaction – OPTN
The recorded move for OPTN in the trading session of this news was +2.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted to the new employees on their respective hire dates (August 16, 2021, and August 23, 2021) with an exercise price equal to the closing price of the company’s common stock as reported by Nasdaq on the grant date (
The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with the company through the applicable vesting date.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.